SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 21.80%, which has investors questioning if this is right time to sell.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...

SELLAS Life Sciences Group, Inc.’s SLS share price has dipped by 17.02%, which has investors questioning if this is right ...

It focuses on the discovery and development of oncology therapeutics. The company’s products include ENITOCICLIB, a CDK9 inhibitor, and several antibody-drug conjugates (ADCs) such as VIP236, VIP943, ...

Aromatase is an enzyme that converts testosterone to estradiol, a type of estrogen. One study found that taking an estrogen blocker called an aromatase inhibitor while on testosterone therapy reduced ...

The inhibition of the BCL-2 family pro-survival proteins, which are frequently overexpressed in B-cell malignancies and pose a fundamental carcinogenic mechanism has been proposed as a promising ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

SELLAS also reported positive data from its Phase 2 trial of SLS009, a selective CDK9 inhibitor, with a median overall survival exceeding 7.7 months. Additionally, the company received FDA Rare ...

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China ...

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China Department of Medicinal Chemistry, School ...

a) Diffusion state probability distributions from three cell lines expressing Histone H2B-Halo, Halo-CaaX, or Halo alone. Shaded bins represent the diffusive states characteristic of each cell line. b ...